AZD9793 / AstraZeneca - LARVOL DELTA

RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC). (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06795022 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • GPC3

Advancing GPC3-positive solid tumor therapy with AZD9793, a novel CD8-guided T cell engager with potent pre-clinical efficacy and superior therapeutic index over GPC3 x CD3 formats (AACR 2025) - "The combined features of bivalent GPC3 binding, CD8-biased engagement, and low-affinity TCR binding enhance AZD9793 cytotoxic potency against tumor cells while minimizing the risk of cytokine release and associated toxicities. These findings support the ongoing clinical evaluation of AZD9793 as a promising therapeutic for patients with GPC3-positive solid tumors."

Preclinical • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • GPC3 • IFNG

RHEA-1: First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=304 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

RHEA-1: First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - P1/2 | N=304 | Not yet recruiting | Sponsor: AstraZeneca

New P1/2 trial • Hepatocellular Cancer • Oncology • Solid Tumor